Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis

alexandrossfakianakis shared this article with you from Inoreader Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis Via Blood Cancer Journal - Issue - nature.com science feeds Blood Cancer Journal, Published online: 19 April 2022; doi:10.1038/s41408-022-00662-0 Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.